| mRNA |
Doxorubicin |
gCSI |
pan-cancer |
AAC |
0.26 |
4e-07 |
| mRNA |
FH535 |
GDSC1000 |
pan-cancer |
AAC |
0.17 |
5e-07 |
| mRNA |
UNC0638:navitoclax (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.18 |
1e-06 |
| mRNA |
BRD-A02303741:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.17 |
2e-06 |
| mRNA |
TW 37 |
GDSC1000 |
pan-cancer |
AAC |
0.15 |
2e-06 |
| mRNA |
tretinoin:navitoclax (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.16 |
5e-06 |
| mRNA |
temsirolimus |
GDSC1000 |
pan-cancer |
AAC |
0.15 |
5e-06 |
| mRNA |
navitoclax:piperlongumine (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.16 |
9e-06 |
| mRNA |
Bleomycin |
GDSC1000 |
pan-cancer |
AAC |
0.15 |
1e-05 |
| mRNA |
decitabine:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.14 |
1e-05 |